<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04388397</url>
  </required_header>
  <id_info>
    <org_study_id>02090520</org_study_id>
    <nct_id>NCT04388397</nct_id>
  </id_info>
  <brief_title>Immediate-access Arteriovenous Versus Standard Arteriovenous Grafts in Hemodialysis Patients</brief_title>
  <official_title>Immediate-access Arteriovenous Versus Standard Arteriovenous Grafts in Hemodialysis Patients: A Randomized Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Egyptian Biomedical Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Egyptian Biomedical Research Network</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arteriovenous fistulae (AVF) are considered the main access for hemodialysis (HD).
      Arteriovenous grafts (AVGs) are an alternative access modality in patients with exhausted
      native venous access. Immediate-access arteriovenous grafts (IAAVGs) is a new modality in
      which dialysis can be started immediately to avoid complications of central venous catheters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aimed to evaluate and compare patency rate and complications of standard
      arteriovenous grafts (SAVGs) and immediate-access arteriovenous grafts (IAAVGs) in end stage
      renal disease (ESRD) patients for one year after the intervention. Patients were randomly
      divided into two groups: SAVGs group and IAAVGs group. Patients with ESRD with no chance for
      native AVF were examined clinically and by duplex ultrasonography preoperatively. Follow up
      was for one year. Primary end points were the success rate, complications rate (hematoma,
      pseudo-aneurysm, graft site infection, systemic bacteremia), time of first cannulation.
      Secondary end points were primary and secondary patency within one year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2017</start_date>
  <completion_date type="Actual">April 10, 2020</completion_date>
  <primary_completion_date type="Actual">April 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>1 year</time_frame>
    <description>Patency of hemodialysis access</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Success rate</measure>
    <time_frame>24 hours</time_frame>
    <description>successful graft procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications rate</measure>
    <time_frame>1 year</time_frame>
    <description>Any graft complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">477</enrollment>
  <condition>Hemodialysis Access Failure</condition>
  <arm_group>
    <arm_group_label>Immediate-access Arteriovenous Grafts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate-access Arteriovenous Grafts as a vascular access for hemodialysis patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Arteriovenous Grafts</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Arteriovenous Grafts as a vascular access for hemodialysis patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Arteriovenous Grafts</intervention_name>
    <description>Arteriovenous fistulae (AVF) are considered the main access for hemodialysis (HD). Arteriovenous grafts (AVGs) are an alternative access modality in patients with exhausted native venous access. Immediate-access arteriovenous grafts (IAAVGs) is a new modality in which dialysis can be started immediately to avoid complications of central venous catheters.</description>
    <arm_group_label>Immediate-access Arteriovenous Grafts</arm_group_label>
    <arm_group_label>Standard Arteriovenous Grafts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult hemodialysis patients

        Exclusion Criteria:

          -  Significant cardiorespiratory comorbidities.

          -  Peripheral vascular disease.

          -  Pregnancy or lactation.

          -  Severe bleeding disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Tawfik, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Zagazig University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine, Zagazig University</name>
      <address>
        <city>Zagazig</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Zagazig</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 9, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

